Evidence map›Paper›PMID 25600007›Full record

ArticleCancer epidemiology2015

ABO blood types and cancer risk--a cohort study of 339,432 subjects in Taiwan.

Wenjie Sun, Chi-Pang Wen, Jie Lin, Christopher Wen, Xia Pu, Maosheng Huang, Min Kuang Tsai, Chwen Keng Tsao, Xifeng Wu, Wong-Ho Chow

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer epidemiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 2 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Wenjie SunDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA.
Chi-Pang WenInstitute of Population Health Science, National Health Research Institutes, Zhunan, Taiwan; China Medical University Hospital, Taichung, Taiwan.
Jie LinDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Christopher WenDepartment of Radiological Sciences, University of California at Irvine, Irvine, CA, USA.
Xia PuDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Maosheng HuangDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Min Kuang TsaiInstitute of Population Health Science, National Health Research Institutes, Zhunan, Taiwan.
Chwen Keng TsaoMJ Health Management Institution, Taipei, Taiwan.
Xifeng WuDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: xwu@mdanderson.org.
Wong-Ho ChowDepartment of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
The University of Texas MD Anderson Cancer Center · USChina Medical University · TWNational Health Research Institutes · TWTulane University · USUniversity of California, Irvine · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

backgroundThe associations of laboratory-based ABO phenotypes with cancer risks and mortality have not been systematically determined.

methodsThe study subjects were 339,432 healthy individuals with laboratory-based blood types from a Taiwan cohort.

resultsCompared to blood type O, blood type A was significantly associated with an elevated risk of stomach cancer incidence (Hazard Ratio [HR], 1.38 [95% CI, 1.11-1.72]) and mortality (HR, 1.38 [95% CI, 1.02-1.86]) compared with blood type O, after adjusting for age, sex, education, smoking, alcohol drinking, physical activity, and body mass index. Non-O blood types were associated with an elevated risk of pancreatic cancer, with blood type B reaching statistical significance for incidence (HR, 1.59 [95% CI, 1.02-2.48]) and mortality (HR, 1.63 [95% CI, 1.02-2.60]). In contrast, kidney cancer risk was inversely associated with blood type AB (HR, 0.41 [95% CI, 0.18-0.93]) compared to type O.

conclusionCancer risks vary in people with different ABO blood types, with elevated risks of stomach cancer associated with blood type A and pancreatic cancer associated with non-O blood types (A, B, and AB).

Indexed as

ABO Blood-Group SystemAdultCohort StudiesFemaleHumansMaleNeoplasmsRisk FactorsTaiwanABO Blood-Group SystemABO blood typeCancer mortalityCancer riskCohort

Identifiers

PMID25600007
PMCPMC4993100
OpenAlexW2038469712

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.